Clinical Trial Update: Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

This is an update on a Phase 2 clinical trial evaluating neoadjuvant immune checkpoint blockade for patients with resectable malignant pleural mesothelioma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Mesothelioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING